ライフサイエンスコーパス: alpha particle

1 doses (50 mGy for gamma-rays and 25 mGy for alpha-particles).

2 isms because of the unique properties of the alpha-particle.

3 Auger or conversion electrons or beta(-) or alpha particles.

4 lls by either a single or an exact number of alpha particles.

5 as produced by fibroblasts after exposure to alpha particles.

6 al interactions were seen between X-rays and alpha particles.

7 elated energy resolution values of 2.4% with alpha particles.

8 gamma-rays and 5 MeV He(2+) ions to simulate alpha particles.

9 er, selectively targets bone metastases with alpha particles.

10 ear energy transfer (LET) radiation, such as alpha-particles.

11 ration of 3 new atoms, yielding a total of 4 alpha-particles.

12 i) that lead to the emission of a total of 4 alpha-particles.

13 ighting the higher intrinsic cytotoxicity of alpha-particles.

14 ast cultures exposed to very low fluences of alpha-particles.

15 oid fibroblasts irradiated with 0.3-3 cGy of alpha-particles.

16 es of human cells exposed to low fluences of alpha-particles.

17 in cultures exposed to very low fluences of alpha-particles.

18 cts as an in vivo generator of 4 high-energy alpha-particles.

19 -of-function mutant cells, were sensitive to alpha-particles.

20 one metastases with high-energy, short-range alpha-particles.

21 to the high LET (linear energy transfer) of alpha-particles.

22 optimal biological effectiveness of emitted alpha-particles.

23 ype damage induced by gamma-rays, but not by alpha-particles.

24 ated cells, fibroblasts that were exposed to alpha particles (0.4-19 cGy) had significant increases i

25 =50-80 mum) combined with the short range of alpha-particles (4-5 cell diameters) may result in only

26 Processes such as the scattering of alpha particles ((4)He), the triple-alpha reaction, and

27 opic resolution is achieved for both (241)Am alpha particles (5.49 MeV) and (241)Am gamma-rays (59.5

28 ne population of cells with a lethal dose of alpha-particles, a decreased bystander mutagenesis was u

29 The alpha-particle absolute detection efficiencies ranged fr

30 Published values of alpha-particle absorbed fraction phi in the skeletal tis

31 Furthermore, variations in alpha-particle absorbed fraction with marrow cellularity

32 ines (a) chord-based techniques for tracking alpha-particles across bone trabeculae, endosteum, and m

33 The energy loss of the alpha-particles after traversing the sample was converte

34 ted treatment approach as the short range of alpha-particles allows effective treatment of local lesi

35 Although alpha particles alone showed no inter-track interactions

36 ances were measured over this time period by alpha particle and thermal ionization mass spectrometry

37 inciples calculations of processes involving alpha particles and alpha-like nuclei have so far been i

38 ate calculation of the elastic scattering of alpha particles and alpha-like nuclei--nuclei with even

39 current study, AL cells were irradiated with alpha particles and responses of bystander cells were in

40 neighboring cells not directly traversed by alpha particles and that cell-cell communication process

41 eing the daughter and thus the source of the alpha-particle and beta emissions.

42 nanotube conjugates were labelled with both alpha-particle and gamma-ray emitting isotopes, at high

43 the delayed coincidence between the outgoing alpha-particle and the neutron.

44 etal bone are 0.81, 0.80, and 0.55 for 6-MeV alpha-particles and are 0.74, 0.72, and 0.43 for 9-MeV a

45 ormation was initiated using radon simulated alpha-particles and cells evaluated as primary, secondar

46 Using beam currents of 50-60 microA alpha-particles and irradiation times of 1.5-4.5 h, the

47 tors were calculated for electrons, photons, alpha-particles, and for (18)F, (90)Y, (99m)Tc, (111)In,

48 neighboring cells not directly traversed by alpha-particles, and that cell-cell communication proces

49 mage), followed by 400 keV He(+) (simulating alpha-particle annealing).

50 Targeted alpha-particle antivascular therapy is shown for the fir

51 The biological effects of a single alpha particle are currently unknown.

52 alpha-Particles are highly potent, short-range radiation

53 Alpha-particles are of current interest in radionuclide

54 alpha-Particles are suitable to treat cancer micrometast

55 clinical trials emphasize the importance of alpha particles as a new therapeutic modality in patient

56 Our results indicate that alpha particle-associated increases in cell growth corre

57 cell was irradiated with either 1,2,4, or 8 alpha particles at a linear energy transfer of 90 keV/mi

58 e investigated the precipitation kinetics of alpha' particles based on the sink density, using both t

59 In recent years, new alpha-particle-, beta(-)-particle-, and Auger electron-e

60 ss exceeded that of a monoenergetic 5.77-MeV alpha particle, but not for (223)Ra.

61 rease the effectiveness corresponding to the alpha particles by more than 100% and also, potentially

62 rved in cell cultures exposed to fluences of alpha-particles by which only a very small fraction of t

63 A single, high linear energy transfer alpha particle can kill a target cell.

64 outcomes, increasing evidence indicates that alpha particles can cause alterations in DNA in the abse

65 densely ionizing alpha-particles (mean of 1 alpha-particle/cell) and analyzed the chromosome aberrat

66 e, implying that cells traversed by multiple alpha particles contribute most of the risk.

67 hondrial dynamics and functions triggered by alpha particle damage to the mitochondria in human small

68 served, but resistance to clustered, complex alpha-particle damage was substantially lower than to eq

69 Radiation damage from the alpha-particle decay of Pu creates numerous defects in t

70 a-particle-emitting radionuclides with 4 net alpha-particle decays that can be used therapeutically.

71 h and 168 h post-injection for quantitative alpha -particle digital autoradiography and hematoxylin

72 ds of 130-microm diameter yielded an average alpha-particle dose of 3.7 Gy to the spheroids, resultin

73 The results show that, for low alpha-particle dose, the number of apoptotic signals dec

74 The induction of cx43 was observed by mean alpha-particle doses as low as 0.16 cGy, and also in cel

75 tion of radiation-induced recovery caused by alpha-particles during alpha-decay events has not been p

76 and irradiated their nuclei with exactly one alpha particle each.

77 20% of randomly selected A(L) cells with 20 alpha particles each results in a mutant fraction that i

78 domly selected cells were irradiated with 20 alpha particles each.

79 lted in diagnostically significant levels of alpha particle emission.

80 It is generally assumed that alpha-particle emission by the parent radionuclide will

81 TAT takes advantage of tumor-localized alpha-particle emission to break disease-associated cova

82 l characteristics (short half-life, high LET alpha-particle emissions).

83 (225)Ac decays via multiple alpha-particle emissions.

84 h ionization-density radiations, such as the alpha-particles emitted by radon gas or the heavy-ions u

85 DTCs both within and beyond the range of the alpha-particles emitted from (223)Ra in bone for both MC

86 g of cellular survival following exposure to alpha-particles emitted from radium-223 ((223)Ra) using

87 tibody 81C6 labeled with the 7.2-h-half-life alpha-particle emitter (211)At might be a valuable endor

88 e rat variant of HER-2/neu, labeled with the alpha-particle emitter (213)Bi to treat widespread metas

89 alpha-Particle emitter (213)Bi-based radioimmunotherapy

90 (89)Zr, and (124)I; beta-emitter (131)I; and alpha-particle emitter (225)Ac for potential use in CLI.

91 s study, we investigated the efficacy of the alpha-particle emitter (225)Ac, parent of (213)Bi, in a

92 escalation study of HuM195, labeled with the alpha-particle emitter 213Bi (half-life = 45.6 min), wer

93 i-PSMA antibody, J591, radiolabeled with the alpha-particle emitter 213Bi (T(1/2), 45.6 min.) has bee

94 contribution of daughter decays in cellular alpha-particle emitter dose calculations.

95 ovide guidance and recommendations for human alpha-particle emitter dosimetry.

96 This is the first trial using an alpha-particle emitter in humans.

97 r atmosphere induced, e.g., by a radioactive alpha-particle emitter like (210)Po.

98 would be the case for a low-energy beta- or alpha-particle emitter localized on the bone surfaces.

99 The design and optimization of alpha-particle emitter radiopharmaceutical therapy (alph

100 of the field that are pertinent to targeted alpha-particle emitter therapy and to provide guidance a

101 ive targeting of hematopoietic cells with an alpha-particle emitter, bismuth-213 ((213)Bi)-labeled an

102 unotherapy using (225)Ac, a highly cytotoxic alpha-particle emitter, has potential for treating advan

103 tudy shows that patient imaging of 213Bi, an alpha-particle emitter, labeled to HuM195 is possible an

104 Simulations were performed for the alpha-particle emitters (211)At, (213)Bi, and (225)Ac.

105 Targeted radiopharmaceutical therapy with alpha-particle emitters (alphaRPT) is advantageous in ca

106 Alpha-particle emitters are currently being considered f

107 al of PSMA-targeting liposomes encapsulating alpha-particle emitters for selective antivascular alpha

108 Alpha-particle emitters have a high linear energy transf

109 Radiobiological studies of alpha-particle emitters have been few as they require de

110 Targeted alpha-particle emitters hold great promise as therapeuti

111 lication of radionuclides and, specifically, alpha-particle emitters in nuclear medicine has brought

112 guide the clinical incorporation of targeted alpha-particle emitters in the treatment of several canc

113 However, the dosimetry of alpha-particle emitters is a challenge because the dimen

114 The potential of alpha-particle emitters to treat cancer has been recogni

115 With renewed interest in therapy with alpha-particle emitters, and their potential for sterili

116 simetry for newly developing therapies using alpha-particle emitters.

117 trials of radiopharmaceuticals labeled with alpha-particle emitters.

118 A novel alpha-particle emitting monoclonal antibody construct ta

119 Radiotherapy using an alpha-particle emitting radionuclide has emerged as a pr

120 Preclinical evaluation of alpha particle-emitting 213Bi-labeled antibody construct

121 etriamine pentaacetic acid (DTPA)-HuM195, an alpha particle-emitting anti-CD33 antibody construct for

122 oride ([(223)Ra]RaCl2) is the first approved alpha particle-emitting therapy and is indicated for tre

123 SPECT is possible but challenging for alpha (alpha)-particle-emitting radiopharmaceutical therapy (al

124 to analyze the therapeutic effectiveness of alpha-particle-emitting (211)At and (213)Bi conjugated t

125 After extensive preclinical work with alpha-particle-emitting (211)At, we performed a phase I

126 clinical trials for labeling antibodies with alpha-particle-emitting (211)At.

127 e), (203)Pb (a surrogate for the therapeutic alpha-particle-emitting (212)Pb), and theranostic (177)L

128 r cells in the bone marrow, was labeled with alpha-particle-emitting (225)Ac.

129 re, we leveraged that scaffold to synthesize alpha-particle-emitting analogs of L1, (213)Bi-L1 and (2

130 at specific ablation of BM-derived EPCs with alpha-particle-emitting anti-VE-cadherin antibody marked

131 zed, antibody-targeted, in vivo generator of alpha-particle-emitting elements.

132 Cellular incorporation of the alpha-particle-emitting radiochemical ((210)Po-citrate)

133 the therapeutic efficacy and limitations of alpha-particle-emitting radiolabeled compounds by means

134 Targeted alpha-therapy with the alpha-particle-emitting radionuclide (225)Ac (half-life,

135 DOTATATE can chelate the clinically relevant alpha-particle-emitting radionuclide (225)Ac, the labeli

136 (223)Ra is a bone-seeking, alpha-particle-emitting radionuclide approved for the tr

137 (TRT) using targeting moieties labeled with alpha-particle-emitting radionuclides (alpha-TRT) is an

138 Targeted alpha-particle-emitting radionuclides have great potenti

139 The alpha-particle-emitting radionuclides have several physi

140 ha-therapies selectively deliver high-energy alpha-particle-emitting radionuclides to tumor-associate

141 (225)Ac(3+) is a generator of alpha-particle-emitting radionuclides with 4 net alpha-p

142 alpha-Particle-emitting radionuclides, such as (211)At,

143 ng class of targeted cancer therapy in which alpha-particle-emitting radionuclides, such as (227)Th,

144 ting the use of beta-particle, electron, and alpha-particle-emitting radiopharmaceuticals is reviewed

145 en the production of high activity levels of alpha-particle-emitting radiotherapeutics is required.

146 ty, toxicity and chemical characteristics of alpha-particle-emitting, 213Bi and 212Bi radiometal conj

147 alpha-Particle--emitting radionuclides are of increasing

148 (225)Ac, (213)Bi, (211)At, and (223)Ra, the alpha-particle--emitting radionuclides of interest in ra

149 rt range and high local energy deposition of alpha particles enable precise radiation delivery and ef

150 to this approach because the short range of alpha-particles enables localized irradiation of tumor c

151 apeutic efficacy and limitations of targeted alpha-particle endoradiotherapeutic strategies.

152 actinium-225 ((225)Ac) in vivo generator of alpha particles exploits the extreme, selective cytotoxi

153 ent study that gamma-irradiation, as well as alpha-particle exposure, dramatically increases the susc

154 P1 foci yields were significantly reduced in alpha particle exposures compared to X-rays, but these f

155 an cells are exposed to very low fluences of alpha particles, fluences whereby only 1-3% of the cell

156 T) may have the same therapeutic efficacy as alpha-particles for oncologic small disease, with lower

157 that in the presence of a low sink density, alpha' particles form and grow faster due to the existen

158 On the other hand, while alpha' particles form far away from the sink interface w

159 We used alpha particles from an (241)Am source as a proxy for th

160 carbons, (1.3 +/- 0.7) x 10(8) sr(-1) J(-1) alpha particles from laser-driven proton-boron fusion re

161 d involving DNA damage to bronchial cells by alpha particles from radon progeny.

162 Ever since Ernest Rutherford scattered alpha-particles from gold foils, collision experiments h

163 esponse for protons, carbon and helium ions (alpha particles) from 0.1 to above 10 MeV and measuremen

164 s independent of radiation quality, but that alpha particles generated substantially more sublethal d

165 Conjugates labelled with alpha-particle-generating (225)Ac were found to clear ra

166 evaluates targeted liposomes loaded with the alpha-particle generator (225)Ac to selectively kill pro

167 e of [(212)Pb]Pb-DOTAM-GRPR1, comprising the alpha-particle generator, (212)Pb, combined with a GRPR-

168 rtial confinement fusion that determines the alpha-particle heating expected to trigger a burn wave i

169 An alpha particle (helium-4 nucleus) comprises two protons

170 null functions are significantly reduced for alpha particles if >/=3 attributes are measured or for b

171 first proof-of-concept for systemic targeted alpha particle immunotherapy in humans.

172 Alpha-particle immunotherapy by targeted alpha-emitters

173 r than for a Poisson-distributed mean of one alpha particle, implying that cells traversed by multipl

174 ttributable to charge transfer of solar wind alpha particles in the cometary coma.

175 a significant contribution of the secondary alpha particles in total effectiveness in proton therapy

176 We have found that a relatively low dose of alpha particles indeed results in the generation of extr

177 The emitted high-energy alpha particles induce DNA double-strand breaks that mig

178 The high energy and short range of the alpha-particles induce antitumor activity, driven by the

179 Thus, alpha-particle induced annealing occurs and must be cons

180 d to the in vivo condition in the context of alpha-particle-induced carcinogenesis in the respiratory

181 ructure" of each complex exchange we predict alpha-particle-induced damage to be repaired at specific

182 ults indicate that the initiating target for alpha-particle-induced genetic changes can be larger tha

183 novel solid tumor management strategy using alpha-particle interstitial brachytherapy, may address t

184 These suggested that alpha-particle-irradiated zebrafish embryos could releas

185 idemiologic data on lifelong detriment after alpha-particle irradiation and its dosimetry allowed cal

186 more robust to damage created by high-energy alpha-particle irradiation as compared to monolayer grap

187 fertilization (hpf) subjected to a low-dose alpha-particle irradiation can release a stress signal i

188 electronic excitations induced by proton and alpha-particle irradiation cause ionization of DNA, resu

189 tely measures cancer cellular sensitivity to alpha-particle irradiation could guide and accelerate cl

190 where the vacancies density is controlled by alpha-particle irradiation or thermal-annealing.

191 Methods: Baseline data for risk estimates of alpha-particle irradiation were collected from published

192 ompasses three populations: those exposed to alpha-particle irradiation, those with a cancer diagnosi

193 eatment procedure, not clearly linked to the alpha-particle irradiation, with no observed hematologic

194 e findings suggest that internally delivered alpha-particle irradiation-induced loss of tubular epith

195 ed in cells held in confluence for 6 h after alpha-particle irradiation.

196 the biological outcome for cells exposed to alpha-particle irradiation.

197 f cancer cell survival following exposure to alpha-particle irradiation.See related commentary by Sgo

198 ous-to-crystalline transition process during alpha-particle irradiations using in situ transmission e

199 The linear energy transfer of alpha particles is several hundredfold greater than that

200 illegitimate repair of damage from a single alpha-particle is a single complex exchange.

201 rmal human lung fibroblasts to a low dose of alpha particles like those emitted by radon/radon progen

202 The mechanism(s) by which alpha particles like those emitted from inhaled radon an

203 The high energy and short range of alpha-particles make them attractive for targeted radiot

204 and fetal tissues where exposure to a single alpha particle may kill or damage critical cells.

205 Although direct nuclear traversals by alpha particles may be involved in mediating these outco

206 In addition, cytoplasmic traversal by alpha particles may be more dangerous than nuclear trave

207 oblasts, we investigated the hypothesis that alpha particles may induce DNA damage via the generation

208 tigated the hypothesis that densely ionizing alpha particles may induce the intracellular generation

209 ks (involving cellular traversal by multiple alpha particles) may overestimate low-level (involving o

210 e and HPRT mutations by very low fluences of alpha particles (mean doses 0.17-0.5 cGy) was measured.

211 ocytes in vitro with 0.5 Gy densely ionizing alpha-particles (mean of 1 alpha-particle/cell) and anal

212 gh activity levels, which can be hindered by alpha-particle-mediated radiolytic effects on labeling c

213 encies of cultured cell studies, we examined alpha-particle microbeam irradiation-induced bystander e

214 On the one hand, MeV-class alpha particles must stay confined to heat the plasma.

215 -nuclei therapy (with argon, carbon, helium [alpha particles], neon, nitrogen, and silicon) have been

216 However, irradiation, such as from the alpha-particle of the alpha-decay event, can itself indu

217 109,000 +/- 22,000 ph/MeV at excitation with alpha-particles of (241)Am.

218 Since 211 At emits alpha-particles of high linear energy transfer, but with

219 cts of exposure to high and very low fluence alpha-particles on the G1 checkpoint were investigated i

220 effect may contribute to the prompt loss of alpha particles or to crashes and disruptions that are o

221 pRb, p34cdc2, and cyclin B1) was observed in alpha-particle or gamma-irradiated human fibroblasts.

222 of either high linear energy transfer (LET) alpha-particles or low-LET gamma-rays leads to stimulati

223 Cells were exposed to X-rays, alpha particles, or combinations, with different doses a

224 c response of DNA to irradiating protons and alpha-particles, our first-principles dynamics simulatio

225 ribution of these agents at the scale of the alpha-particle pathlength.

226 in the core respond poorly because of short alpha-particle penetrance.

227 E was deemed the superior agent for targeted alpha-particle peptide receptor radionuclide therapy.

228 uent mammalian cell population with a single alpha particle per cell results in a mutant yield simila

229 the short path lengths and high energies of alpha-particles produce optimal cytotoxicity at small ta

230 ainment requires control over the content of alpha particles produced by D-T fusion reactions.

231 due to secondary reactions induced by alpha (alpha) particles produced in the primary reactions.

232 eted radiopharmaceutical therapy (TRT) using alpha-particle radiation is a promising approach for tre

233 liminating microscopic residual disease with alpha-particle radiation is theoretically appealing.

234 Targeted antivascular alpha-particle radiation remodels the glioblastoma vascu

235 mbryo fibroblasts exposed to either gamma or alpha-particle radiation revealed a total lack of G1 arr

236 mode ESI have been subjected to polonium-210 alpha-particle radiation to reduce the average charge st

237 Targeted alpha-particle radiation using the radioisotope (225)Ac

238 ent approaches and improved understanding of alpha-particle radiopharmaceutical therapies.

239 PSMA-targeted (211)At- 6: alpha-particle radiotherapy yielded significantly improv

240 verestimate low-level (involving only single alpha particles) radon risks.

241 a significant contribution to the yield from alpha-particle self-heating and evidence for the 'bootst

242 Alpha particles serve as a surrogate for fission fragmen

243 is by exposing cells to very low fluences of alpha-particles, similar to those emitted by radon gas,

244 tively charged) ions generated using a 210Po alpha particle source.

245 ilable alpha-particle spectrometer and 210Po alpha-particle source were used to determine the mass of

246 A commercially available alpha-particle spectrometer and 210Po alpha-particle sou

247 low-level liquid scintillation counting and alpha-particle spectrometry.

248 mple was converted to a mass using tabulated alpha-particle stopping powers.

249 vels of telomerase activity were detected in alpha-particle survivors while robust telomerase activit

250 horter range and more potent cytotoxicity of alpha-particles than of beta-particles, (211)At-labeled

251 Two characteristics of alpha-particles that enhance their potential for targete

252 -induced DNA damage by energetic protons and alpha-particles, the chemistry and physics of which are

253 18 h coculture with cells irradiated with 20 alpha-particles, the fraction of bystander cells with mu

254 ns and neutrons; these later combine to form alpha particles, then (12)C nuclei via the triple-alpha

255 Augmentation of antibody-targeted alpha-particle therapies with tumor-responsive liposomes

256 options and poor patient outcomes, targeted alpha-particle therapy (TAT) represents a promising deve

257 Targeted alpha-particle therapy has been shown to kill tumors tha

258 These properties make targeted alpha-particle therapy ideal for the elimination of mini

259 rformed a phase I trial with intraperitoneal alpha-particle therapy in epithelial ovarian cancer usin

260 afety, feasibility, and activity of targeted alpha-particle therapy in the treatment of small-volume

261 a-particle therapy, suggesting that targeted alpha-particle therapy may offer a promising treatment o

262 Antivascular alpha-particle therapy of glioblastoma in the transgenic

263 c agent is a promising strategy for targeted alpha-particle therapy of HER2-expressing cancers.

264 Targeted alpha-particle therapy offers the possibility of selecti

265 m) of alpha-emitting radioisotopes, targeted alpha-particle therapy offers the potential for more spe

266 In preparation for an alpha-particle therapy trial using 1-7 MBq of (224)Ra, t

267 We previously investigated targeted alpha-particle therapy with (225)Ac-E4G10 as an antivasc

268 A theoretical drawback to alpha-particle therapy with 213Bi is the short range of

269 mately, randomized trials comparing targeted alpha-particle therapy with standard approaches will be

270 ragments (sdAbs) are attractive for targeted alpha-particle therapy, particularly with (211)At, becau

271 )Th is a promising radioisotope for targeted alpha-particle therapy.

272 e of dasatinib into tumor was enhanced after alpha-particle therapy.

273 easurements for the traversal of exactly one alpha particle through a cell nucleus.

274 It produces 5 alpha-particles through its decay, with the clinically a

275 targeted radiotherapies can deliver multiple alpha particles to a receptor site dramatically amplifyi

276 y of antigen targeting with the lethality of alpha particles to eradicate cancerous cells.

277 s been constructed that selectively delivers alpha-particles to prostate cancer cells for potent and

278 y (TAT) delivers high-linear-transfer-energy alpha-particles to tumors with the potential to generate

279 lones radioresistant to either gamma-rays or alpha-particles to understand possible mechanisms in rad

280 The measured distributions of alpha-particle tracks per cell were subjected to statist

281 s developed, thereby resulting in observable alpha-particle tracks that were scored.

282 Although there was indication that alpha particle traversal through cellular cytoplasm was

283 formation is a consequence of direct nuclear alpha-particle traversal and show that the likely produc

284 ial cells are frequently exposed to multiple alpha-particle traversals.

285 3)Pb/(212)Pb theranostic pair for PSMA-based alpha-particle TRT in advanced PC.

286 A technique to assess the effects of single alpha particles uses a charged-particle microbeam, which

287 The more potent cytotoxicity of alpha-particles warrants their continued investigation a

288 , the measured oncogenicity from exactly one alpha particle was significantly lower than for a Poisso

289 light yield under excitation with X-rays and alpha-particles was investigated.

290 oses as low as 2-mGy gamma-rays and 0.29-mGy alpha-particles were sufficient to produce an observable

291 icles and are 0.74, 0.72, and 0.43 for 9-MeV alpha-particles, where each is evaluated at ICRP referen

292 s are very rarely traversed by more than one alpha particle, whereas at higher radon levels-at which

293 loits the extreme, selective cytotoxicity of alpha particles, while providing a feasible half-life to

294 46 min) radionuclide that emits high energy alpha-particles with an effective range of 0.07-0.10 mm

295 uniform microdistributions of the delivered alpha-particles within established solid tumors improve

296 ncogenic transforming effects of exactly one alpha particle without the confounding effects of multip

297 toma with cytotoxic short-range, high-energy alpha-particles would be an effective therapeutic approa

298 composition with approximately 74 wt.% SiO2 (Alpha Particle X-Ray Spectrometer analysis).

299 Chemical analyses of rocks by the Alpha Particle X-ray Spectrometer are consistent with pi

300 "Jake_M," the first rock analyzed by the Alpha Particle X-ray Spectrometer instrument on the Curi

301 Element analyses by Alpha Particle X-ray Spectrometers on the Mars Explorati